TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04849676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual neurofeedback
Description: Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual neurofeedback
Description: Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual neurofeedback
Description: Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual neurofeedback
Description: Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity.
Study: NCT06317415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeChat-based health education on antibiotic use
Description: Health education based on the WeChat platform includes popular science articles on WeChat public Platform and health education videos.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular public health education
Description: Health education information on the prevention and control of common chronic diseases
Study: NCT06479291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Tablet
Description: Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eltrombopag
Description: Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
Study: NCT06496425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Those randomized to the exercise and music group will receive pre-recorded music playlists along with the exercise. During the strength training (ST), participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), we will adjust the tempo of playlists to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
Study: NCT06271681

Intervention type: DRUG
Group type: OTHER
Intervention: 15-valent pneumococcal conjugate vaccine
Description: FDA approved pneumococcal vaccines 15 valent conjugate vaccine administered at enrollment

Intervention type: DRUG
Group type: OTHER
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: 23 valent pneumococcal vaccine administered 8 weeks after initial 15 valent pneumococcal conjugate vaccine
Study: NCT05006989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Powder
Description: Administered 10 grams/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Administered 10 grams/day
Study: NCT05655221

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1344
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1344
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1344
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1344
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1344
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1344
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1344
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)
Study: NCT04771390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Adult tablet
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Adult tablet
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Adult tablet
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Adult tablet
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Pediatric tablet
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Pediatric tablet
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Pediatric tablet
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Pediatric tablet
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Pediatric tablet
Description: Tablet, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral solution
Description: Oral solution after reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral solution
Description: Oral solution after reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral solution
Description: Oral solution after reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral suspension
Description: Oral suspension after reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral suspension
Description: Oral suspension after reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral suspension
Description: Oral suspension after reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral suspension
Description: Oral suspension after reconstitution
Study: NCT05655221

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)
Study: NCT06232798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a dual energy catheter (RF and PFA) or PFA catheter only will be to treat PeAF,Cardiac Pulsed Electric Field Ablation Catheter
Description: This study will be used two catheters, the contact force sensing catheter able to deliver both RF and PFA energy, this catheter provides both the radiofrequency (RF) energy and pulsed field ablation (PFA) energy to the catheter through the toggling of the two energy sources on the generator monitor. Another catheter is PFA catheter only.
Study: NCT05588232

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scheduled outpatient interventions in interventional cardiology
Description: coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scheduled outpatient interventions in interventional cardiology
Description: coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
Study: NCT06232798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: catheter ablation
Study: NCT06112392

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
Description: Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treatment （Oral standard anti-Parkinson's drugs）
Description: Treatment （Oral standard anti-Parkinson's drugs）
Study: NCT05778526

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional social skills training
Description: There are a total of 12 training sessions for 3 weeks (4 sessions per week). Each session lasts for a maximum of 20 minutes. Four modules will be covered in the 3-week training: (1) how to introduce yourself and basic social skills; (2) how to listen to others; (3) how to share with others; (4) learn to know how people feel and how to empathise.
Study: NCT06348225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise or heat treatment
Description: Interventions will be each of the four arms described previously, administered \~1 week apart in a randomized, counter-balanced fashion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise or heat treatment
Description: Interventions will be each of the four arms described previously, administered \~1 week apart in a randomized, counter-balanced fashion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise or heat treatment
Description: Interventions will be each of the four arms described previously, administered \~1 week apart in a randomized, counter-balanced fashion.
Study: NCT05611398

Intervention type: PROCEDURE
Intervention: Orthopedic Surgery
Description: A complete retrospective chart review was performed for all the patients' records and included all patients aged 18 years or higher who presented to Arrowhead Regional Medical Center with long bone fractures with Injury Severity Score \<16 and their repair and lactate levels at the time of surgery

Intervention type: PROCEDURE
Intervention: Orthopedic Surgery
Description: A complete retrospective chart review was performed for all the patients' records and included all patients aged 18 years or higher who presented to Arrowhead Regional Medical Center with long bone fractures with Injury Severity Score \<16 and their repair and lactate levels at the time of surgery
Study: NCT05000060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing/1 week
Description: Time of restart of antiplatelet therapy is one week after injury

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing/3 weeks
Description: Time of restart of antiplatelet therapy is left to treating clinician discretion
Study: NCT06498999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-STEP-Training Program for Social Media Addiction (4-STEP-TPS)
Description: 4 Modules with 1 Module being delivered in 1 weekly session of approximately 90 minutes. The details of each module/step is described as follows:~Step 1 (Module 1): S = Screening, Assessment and Psychoeducation: Involves screening and assessment of the problem, interpretation of the results, feedback and psychoeducation, identifying and breaking the resistance, motivation, and conceptualization.~Step 2 (Module 2): T = Treatment Conceptualization and Planning: Involves pattern identification, distortion identification, as well as pattern and distortions modifications.~Step 3 (Module 3): E = Effective Management Strategies: Involves management strategies to treat the earlier identified patterns as well as the implementation and confirmation of activities via a Pattern Schedule Chart.~Step 4 (Module 4): P = Prevention (Lapse-Relapse): Involves self-reflection and support building, monitoring and dependency check and slip plans and support additions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-STEP-Training Program for Social Media Addiction (4-STEP-TPS)
Description: 4 Modules with 1 Module being delivered in 1 weekly session of approximately 90 minutes. The details of each module/step is described as follows:~Step 1 (Module 1): S = Screening, Assessment and Psychoeducation: Involves screening and assessment of the problem, interpretation of the results, feedback and psychoeducation, identifying and breaking the resistance, motivation, and conceptualization.~Step 2 (Module 2): T = Treatment Conceptualization and Planning: Involves pattern identification, distortion identification, as well as pattern and distortions modifications.~Step 3 (Module 3): E = Effective Management Strategies: Involves management strategies to treat the earlier identified patterns as well as the implementation and confirmation of activities via a Pattern Schedule Chart.~Step 4 (Module 4): P = Prevention (Lapse-Relapse): Involves self-reflection and support building, monitoring and dependency check and slip plans and support additions
Study: NCT05641753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab Cartridge
Description: Injectable PCSK9 inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium Tablets
Description: HMG-CoA reductase inhibitor for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe Tablets
Description: Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiocatheter 20IV
Description: Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Wire
Description: Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlycoCheck Glycocalyx Measurement Software
Description: Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
Study: NCT04932551

Intervention type: OTHER
Intervention: Questionnaire
Description: physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.
Study: NCT05568381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital CBT-I
Description: Sleepio is a digital cognitive behavioral therapy (CBT) program designed to treat insomnia. The program is fully automated, and its underlying algorithms drive the delivery of information, support, and advice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Sleep Health Education package
Description: Wait-listed control participants will have full access to three online modules for the duration of the study. The information in these modules will provide non-tailored basic sleep information and content will contain text and basic images but will not be personalised to the individual participant.
Study: NCT05167318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: frequent standardized oral care
Description: Standardized oral care will be provided every 3-4 hours
Study: NCT06476119

Intervention type: DRUG
Intervention: Adjuvant chemotherapy
Description: adjuvant chemotherapy according to local/ national guidelines

Intervention type: OTHER
Intervention: No adjuvant chemotherapy
Description: no adjuvant chemotherapy
Study: NCT04771390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral suspension
Description: Oral suspension after reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral suspension
Description: Oral suspension after reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral suspension
Description: Oral suspension after reconstitution
Study: NCT04808492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CureWave High Intensity Laser
Description: * The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include:~  * Power (44 Watts)~ * Mode (continues wave)~ * Time on (60000 ms)~ * Time off (1 ms)~ * Repeats (9)~* Distance of electrode from skin will begin 10 from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2 intervals until it is comfortable. The entire process will take approximately 10 minutes.~* The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE.~o Distance of electrode from skin will begin 10 from skin surface. The entire process will take approximately 10 minutes.
Study: NCT06496308

Intervention type: DRUG
Group type: OTHER
Intervention: Orelabrutinib
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: OTHER
Intervention: Orelabrutinib
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine IV will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine IV will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab IV will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: OTHER
Intervention: Venetoclax
Description: Venetoclax PO will be administered as per the schedule specified in the respective arm.
Study: NCT05970536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple vinegar or EDTA 17%
Description: Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple vinegar or EDTA 17%
Description: Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.